Biopharmx (BPMX) Sees Large Volume Increase
Biopharmx Corp (NYSEAMERICAN:BPMX) shares saw strong trading volume on Thursday . 25,619,400 shares traded hands during mid-day trading, an increase of 238% from the previous session’s volume of 7,581,873 shares.The stock last traded at $0.14 and had previously closed at $0.13.
Separately, Maxim Group reaffirmed a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a research note on Friday, December 8th.
The firm has a market cap of $14.93, a P/E ratio of -0.48 and a beta of 1.33.
In other news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of Biopharmx stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Stephen Morlock purchased 330,000 shares of the business’s stock in a transaction dated Friday, November 24th. The shares were purchased at an average cost of $0.15 per share, for a total transaction of $49,500.00. The disclosure for this purchase can be found here.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.